OpenNashEarnings

McKesson (MCK) · Health Care

McKesson Q2 FY2027 earnings: summary, key numbers & outlook

Results filed 4 Nov 2026 · Quarter ended 30 Sep 2026

Slides (32 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

McKesson deepened its push into specialty and oncology care, extending its CVS Health distribution deal through June 2032 and agreeing to a roughly 49% stake in Option Care Health.

McKesson extended its pharmaceutical distribution partnership with CVS Health through June 2032. Growth came from specialty products sold to health systems and strategic accounts, and from provider solutions and specialty distribution in Oncology & Multispecialty. Prescription Technology Solutions grew on third-party logistics and access solutions, though hub dispensing contributed less. In Medical-Surgical Solutions, a weaker product mix in ambulatory care held back profit. PRISM Vision Group added Spectrum Vision Partners, bringing its network to more than 350 providers.

Management is steering toward complex specialty therapies, community-based care and biopharma services. It signed a deal to invest about $1.4 billion for roughly 49% of Option Care Health and completed the Precision Medicine Group acquisition. It is also pursuing a separation of Medical-Surgical Solutions. The main risk is execution: the Option Care Health deal needs stockholder and regulatory approvals, and the separation and acquisitions may not deliver the intended benefits or hit the planned timelines.

Slides & documents

Open the slide deck (PDF, 32 pages) ↗

McKesson Q2 FY2027 slide deck, page 1McKesson Q2 FY2027 slide deck, page 2McKesson Q2 FY2027 slide deck, page 3McKesson Q2 FY2027 slide deck, page 4McKesson Q2 FY2027 slide deck, page 5McKesson Q2 FY2027 slide deck, page 6

Showing the first 6 of 32 pages.

From McKesson investor relations

SEC filing

Key numbers

Revenue · GAAP
$111.0 billion

up 8% from a year ago

Net income attributable to McKesson · GAAP
$1.2B

up 10% from a year ago

Diluted EPS · GAAP
$10.44

up $1.52 from a year ago

Adjusted diluted EPS · non-GAAP
$11.68

up 18% from a year ago

Operating income · GAAP
1.6B

up 14% from a year ago

Operating cash flow · GAAP
$3.1 billion

Free cash flow · non-GAAP
$2.9 billion

Segment or metricValueChange
North American Pharmaceutical revenue$91.4 billionup 6%
Oncology & Multispecialty revenue$15.0 billionup 24%
Prescription Technology Solutions revenue$1.5 billionup 10%
Medical-Surgical Solutions revenue$3.1 billionup 5%
Where each number comes from
  • Revenue: “Second quarter revenues were $111.0 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes”
  • Net income attributable to McKesson: “Net income attributable to McKesson Corporation | $1,218 | $1,110 | 10% | $1,832 | $1,894 | (3)%”
  • Diluted EPS: “Second quarter earnings per diluted share was $10.44 compared to $8.92 a year ago, an increase of $1.52.”
  • Adjusted diluted EPS: “Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86 a year ago, an increase of 18%”
  • Operating income: “Operating income | 1,604 | 1,407 | 14 | 2,923 | 2,443 | 20 Other income (expense), net | 63 | 62 | 2”
  • Operating cash flow: “During the three months ended September 30, 2026, McKesson generated cash from operations of $3.1 billion, and invested $123 million in capital expenditures”
  • Free cash flow: “invested $123 million in capital expenditures, resulting in Free Cash Flow of $2.9 billion.”
  • North American Pharmaceutical revenue: “Revenues were $91.4 billion, an increase of 6%, driven by increased prescription transaction volumes, including higher volumes from specialty products to health systems and strategic accounts”
  • Oncology & Multispecialty revenue: “Revenues were $15.0 billion, an increase of 24%, driven by growth in provider solutions and specialty distribution.”
  • Prescription Technology Solutions revenue: “Revenues were $1.5 billion, an increase of 10%, driven by increased prescription volumes in third-party logistics and access solutions”
  • Medical-Surgical Solutions revenue: “Revenues were $3.1 billion, an increase of 5%, driven by growth across the extended and ambulatory care channels.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 FY2027vs year agovs last quarter
Revenue$111.0B+7.6%+5.3%
Operating income$1.6B+14.0%+21.6%
Net income$1.2B+9.7%+98.4%
Diluted EPS$10.44+17.0%+102.7%
Free cash flow$3.0B+29.9%—
Gross margin3.6%+0.2 pts+0.1 pts
Operating margin1.4%+0.0 pts+0.1 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Adjusted EPSfiscal 2027$45.60 to $46.40
Revenue growthfiscal 20276% to 10% growth
Effective tax ratefiscal 202718% to 19%
Free cash flowfiscal 2027$4.5 to $4.9 billion

Key takeaways

  1. CVS Health distribution partnership extended to 2032

    McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032. This secures a long-running anchor customer relationship.

  2. McKesson is taking a 49% stake in Option Care Health

    It signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health. The deal targets complex specialty therapies and community-based care, but still needs stockholder and regulatory approvals.

  3. Precision Medicine Group acquisition expands biopharma services

    McKesson completed the acquisition of Precision Medicine Group on November 2, 2026. The company calls it a milestone for its oncology, multispecialty and biopharma services strategy.

  4. Oncology & Multispecialty is the fastest-growing segment

    Segment revenue rose 24% on provider solutions and specialty distribution, and management lifted full-year revenue growth expectations to 20.0% to 24.0%. Management says it is making focused investments to accelerate this and biopharma services.

  5. Medical-Surgical separation proceeds amid ambulatory mix pressure

    McKesson is planning to separate Medical-Surgical Solutions, in which Apollo Funds acquired about a 13% minority stake. Segment profit fell 10% as ambulatory care mix weakened, partly offset by extended care.

Charts

Revenue$111.0B+7.6% y/yQ2 FY27
Q3 FY25: $95.3BQ3 25$95.3BQ4 FY25: $90.8B (worked out from the annual figure)Q4 25$90.8BQ1 FY26: $97.8BQ1 26$97.8BQ2 FY26: $103.2BQ2 26$103.2BQ3 FY26: $106.2BQ3 26$106.2BQ4 FY26: $96.3B (worked out from the annual figure)Q4 26$96.3BQ1 FY27: $105.4BQ1 27$105.4BQ2 FY27: $111.0BQ2 27$111.0B

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$95.3B
Q4 FY25$90.8B *
Q1 FY26$97.8B
Q2 FY26$103.2B
Q3 FY26$106.2B
Q4 FY26$96.3B *
Q1 FY27$105.4B
Q2 FY27$111.0B
Diluted EPS (GAAP)$10.44+17.0% y/yQ2 FY27
Q3 FY25: $6.95Q3 25$6.95Q1 FY26: $6.25Q1 26$6.25Q2 FY26: $8.92Q2 26$8.92Q3 FY26: $9.59Q3 26$9.59Q1 FY27: $5.15Q1 27$5.15Q2 FY27: $10.44Q2 27$10.44
Data
Q3 FY25$6.95
Q1 FY26$6.25
Q2 FY26$8.92
Q3 FY26$9.59
Q1 FY27$5.15
Q2 FY27$10.44

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.4%+0.0 pts y/yQ2 FY27
Q3 FY25: 1.3%Q3 251.3%Q4 FY25: 1.8%Q4 251.8%Q1 FY26: 1.1%Q1 261.1%Q2 FY26: 1.4%Q2 261.4%Q3 FY26: 1.5%Q3 261.5%Q4 FY26: 2.2%Q4 262.2%Q1 FY27: 1.3%Q1 271.3%Q2 FY27: 1.4%Q2 271.4%
Data
Q3 FY251.3%
Q4 FY251.8%
Q1 FY261.1%
Q2 FY261.4%
Q3 FY261.5%
Q4 FY262.2%
Q1 FY271.3%
Q2 FY271.4%
Free cash flow$3.0B+29.9% y/yQ2 FY27
Q3 FY25: -$2.5BQ3 25-$2.5BQ4 FY25: $7.6BQ4 25$7.6BQ1 FY26: -$1.0BQ1 26-$1.0BQ2 FY26: $2.3BQ2 26$2.3BQ3 FY26: $1.1BQ3 26$1.1BQ4 FY26: $3.3BQ4 26$3.3BQ1 FY27: -$332.0MQ1 27-$332.0MQ2 FY27: $3.0BQ2 27$3.0B
Data
Q3 FY25-$2.5B
Q4 FY25$7.6B
Q1 FY26-$1.0B
Q2 FY26$2.3B
Q3 FY26$1.1B
Q4 FY26$3.3B
Q1 FY27-$332.0M
Q2 FY27$3.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is McKesson's strategic deal with Option Care Health?

McKesson agreed to invest about $1.4 billion for roughly 49% of Option Care Health, supporting complex specialty therapies and community-based care. It needs Option Care Health stockholder approval and regulatory approvals.

What happened with McKesson's CVS Health relationship?

McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032.

What is driving growth in McKesson's oncology business?

Oncology & Multispecialty revenue rose 24% on growth in provider solutions and specialty distribution. McKesson also completed the Precision Medicine Group acquisition to advance oncology, multispecialty and biopharma services.

What is happening to Medical-Surgical Solutions?

McKesson plans to separate it into an independent company, and Apollo Funds acquired about a 13% minority stake. Revenue grew 5%, but adjusted profit fell 10% on weaker ambulatory care mix.

How did McKesson raise its full-year outlook?

It raised fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00, and lifted its revenue and operating profit growth ranges. Its segment outlooks for North American Pharmaceutical and Oncology & Multispecialty were also raised.

Call recording

Call recording on YouTube ↗. Official replay ↗.

Read McKesson's official transcript ↗.